Company intelligence / Profile preview

UBE Corporation

minato-ku, TOKYO, JAPANube.com ↗

Ownership: Private
Employees: ~9849
Development stage: Other

Overview

UBE has a track record of commercialized small molecule drugs such as betotastine besilate and prasugrel hydrochloride. The company is advancing new drug candidates in preclinical and clinical stages, including novel CDK7 inhibitors for oncology. It also provides contract manufacturing services for APIs and intermediates, with recent expansion into ADCs and oligonucleotide therapeutics.

Therapeutic areas: NeurologyDermatologyOncologyNephrologyImmunology
Modalities: Small moleculeAntibody-drug conjugateOligonucleotide therapeutics
Industry: Biotech

Drug pipeline

1 asset

Dimethyl carbate

Unknown

Partnerships

Kirilys Therapeutics(licensee of CDK7 inhibitor program)FRONTEO(AI-driven drug repositioning collaboration)

Beyond the preview

Go deeper on UBE Corporation.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on UBE Corporation.

Explore the full profile